<DOC>
	<DOCNO>NCT00007033</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine role magnesium deficiency pathogenesis decrease serum vitamin D reduce bone density child chronic cholestatic liver disease .</brief_summary>
	<brief_title>Study Magnesium Sulfate Children With Reduced Bone Density Secondary Chronic Cholestatic Liver Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive magnesium sulfate IV 1 hour day 3 . Patients receive oral magnesium gluconate supplementation daily . Treatment magnesium sulfate repeat 3-6 month .</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Biliary Atresia</mesh_term>
	<mesh_term>Alagille Syndrome</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis liver disease chronic cholestasis Nonsyndromic intrahepatic cholestasis Alagille 's syndrome Extrahepatic biliary atresia Direct bilirubin great 2 mg/dL OR Bile acid great 20 micromoles/L No hepatic decompensation define one following : Ascites Peripheral edema PT least 4 second longer control Albumin le 3 g/dL Patient Characteristics Renal : No significant renal disease Cardiovascular : No significant cardiovascular disease Pulmonary : No significant pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>Alagille syndrome</keyword>
	<keyword>biliary atresia</keyword>
	<keyword>cholestasis</keyword>
	<keyword>gastrointestinal disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>